Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Podocalyxin (PODXL)
- Target
- PODXL
- Molecular classification
- Transmembrane sialomucin, CD34 family member
01
Overview
Podocalyxin (PODXL) is a single-pass transmembrane sialomucin and major component of the podocyte glycocalyx in the kidney glomerulus, where it maintains open filtration pathways between foot processes through negative charge repulsion. It belongs to the CD34 family, features extensive O- and N-linked glycosylation, and links to the actin cytoskeleton via ERM proteins. Beyond kidney function, it regulates apical domain formation, microvilli induction, cell migration, and invasion; elevated expression correlates with poor cancer outcomes, acting as a decoy receptor for galectin-3 to promote integrin-mediated motility. The protein is 605 amino acids long with a mass of approximately 65 kDa (higher due to glycosylation), including extracellular (33-500), transmembrane (501-521), and cytoplasmic (522-605) domains.
- Other names
- Podocalyxin-like protein 1PC
02
Biological functions
Regulation of cell adhesion and morphologyMaintenance of podocyte foot processes via charge repulsionInduction of microvillus formationPodocyte morphogenesis and differentiationEpithelial polarization and lumen formationCell migration and invasionLinkage to actin cytoskeleton via ERM binding
03
Disease associations
Proteinuric kidney diseaseFocal segmental glomerulosclerosis (FSGS)Cancer progression and metastasis (e.g., colon carcinoma, prostate cancer)Renal insufficiency
04
Safety considerations
Loss-of-function mutations lead to proteinuria, foot process effacement, and renal failureheterozygous mutations associated with late-onset renal insufficiencyoverexpression promotes cancer invasion and metastasis
05
Biomarkers
Podxl expression levels as early biomarker of proteinuric kidney diseasePODXL variants (e.g., p.L442R) in familial FSGS
Beyond the preview
Go deeper on Podocalyxin (PODXL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Podocalyxin (PODXL).